10 assets in Acquired Hypothalamic Obesity

Therapeutic assets addressing Acquired Hypothalamic Obesity, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tirzepatide Acquired Hypothalamic Obesity	Grace Kim	P4	BB (65)
Setmelanotide Acquired Hypothalamic Obesity	Rhythm Pharmaceuticals, Inc.	P3	BB (64)
lb54640 Acquired Hypothalamic Obesity	Rhythm Pharmaceuticals, Inc.	P2	B (57)
Tesofensine Acquired Hypothalamic Obesity	Saniona	P2	B (57)
Beatrolol Acquired Hypothalamic Obesity	Saniona	P2	B (56)
Bivamelagon Acquired Hypothalamic Obesity	Rhythm Pharmaceuticals, Inc.	P2	CCC (53)
Phentermine Acquired Hypothalamic Obesity	Seattle Children's Hospital	P2	CCC (53)
Topiramate Acquired Hypothalamic Obesity	Seattle Children's Hospital	P2	CCC (53)
RM-718 Acquired Hypothalamic Obesity	Rhythm Pharmaceuticals, Inc.	P1/2	CC (47)
Liraglutide Acquired Hypothalamic Obesity	Seoul National University Hospital	Early P1	C (39)